



DOI: 10.5137/1019-5149.JTN.20216-17.1

Received: 25.02.2017 / Accepted: 07.05.2017

Published Online: 12.06.2017

Case Report

Course of Aggressive Somatotroph, Corticotroph and Mammotroph Tumors under Temozolomide: Report of Three Cases and Review of the Literature

Berna İmge AYDOĞAN, Uğur ÜNLÜTÜRK, Rifat EMRAL, Sevim GÜLLÜ

Ankara University, Faculty of Medicine, Department of Endocrinology and Metabolism, Ankara, Turkey

ABSTRACT

Treatment of aggressive pituitary tumors may be challenging. Temozolomide (TMZ) is a promising agent when conventional treatment methods fail. We present three patients with aggressive pituitary tumors with atypical morphology, who were resistant to conventional treatments and treated with TMZ. The first case had a somatotroph adenoma, the second a corticotroph adenoma, and the third a macroprolactinoma. We also reviewed the literature reporting TMZ efficacy in somatotroph, corticotroph and mammotroph tumors of the pituitary gland. TMZ with a schedule of 150–200 mg/m² for 5 days every 28 days was administered to all patients. Even though only the case of macroprolactinoma had a favorable response to TMZ treatment among our patients, both radiological and hormonal recurrence occurred 30 months after the cessation of TMZ treatment. TMZ treatment was then administered again. Cases of somatotroph and corticotroph adenomas had progressed under TMZ treatment and the patients were lost due to mass effect of the tumor. A review of the literature demonstrated 67.3%, 60% and 26.7% overall response rates to TMZ treatment in prolactinoma, corticotropinoma and somatostatinoma cases, respectively. There is still a need to define response criteria uniformly to TMZ treatment in aggressive pituitary tumors. The duration of response should be reported for reliable evaluation of results.

KEYWORDS: Aggressive pituitary adenoma, Cushing's disease, Macroprolactinoma, Somatotroph adenoma, Temozolomide

ABBREVIATIONS: MGMT: O6Methylguanine DNA methyl-transferase, TMZ: Temozolomide, APA: Atypical pituitary adenoma, PC: Pituitary carcinoma, MSH6: DNA mismatch repair protein, PRL: Prolactin

INTRODUCTION

Pituitary adenomas (PAs) are relatively frequent tumors with an estimated prevalence of 80-90 per 100,000 and account for 15% of intracranial neoplasms (25,55). The large majority of pituitary adenomas are benign. However, aggressive, invasive or malignant tumors of the pituitary gland may develop and treatment of these tumors is quite challenging. A classification for pituitary adenomas was developed by World Health Organization (WHO) in 2004 (39). The WHO classification suggested the prediction of potentially "aggressive adenomas" with histopathological features.

Atypical pituitary adenoma (APA) and pituitary carcinoma (PC) were defined according to immunohistochemical staining characteristics and presence of metastasis. Adenomas with atypical morphological features of invasive growth, increased number of mitoses, extensive nuclear staining for P53, and a Ki67 (MIB-1) proliferation index of 3% or more were classified as APAs. In surgical series, APAs were identified in 2.7-14.8% of resected pituitary adenomas (63,76). "Aggressive pituitary adenoma" is a clinical description of tumors characterized by invasion to adjacent tissues, early recurrence and resistance to classical first line treatments. Clinical behavior of aggressive

qr code

Corresponding author: Berna İmge AYDOĞAN

E-mail: imgehalici@gmail.com

adenomas is different from both benign and malign adenomas and they can be considered as an intermediate form. APAs may not be aggressive tumors and also aggressive adenomas may not be APAs. However, atypical histopathology according to WHO criteria was suggested as an independent risk factor for aggressive tumor behavior (1).

PCs and aggressive/atypical adenomas are usually resistant to conventional treatments and have poor prognosis (33,68,76). Conventional chemotherapeutic drugs do not have impact on survival and tumor recurrence in these tumors (33,68). Thus, PCs/APAs require additional treatment modalities when residual or recurrent tumors are resistant to classical treatment options.

Temozolomide (TMZ) is an orally administered, second-generation, alkylating chemotherapeutic drug capable of crossing the blood-brain barrier (5). The principal mechanism responsible for the cytotoxicity of TMZ is the methylation of deoxyribonucleic acid (DNA) that results in strand breaks and cell death (42). TMZ was shown to be a promising chemotherapeutic drug for salvage therapy of aggressive adenomas and PCs. In the last decade, TMZ treatment has been used in aggressive pituitary adenomas and carcinomas that were resistant to classical treatment options. Since the first case of aggressive pituitary adenoma was treated with TMZ, more than 100 cases of pituitary tumors including PCs and aggressive adenomas managed with TMZ have been reported (16,79). Even though these case reports and small series have shown that TMZ could be an alternative treatment option for PCs and aggressive adenomas, there is still a need for more experience in using this drug due to the heterogeneous and limited number of results among same pituitary tumor types. Experience with somatotropinomas is especially limited with only fourteen cases and not sufficient to create a general impression (6,7,12,27,43,50,72).

We therefore present our experience with TMZ in the management of three aggressive pituitary adenomas, somatotroph, corticotroph and mammotroph tumors, refractory to conventional treatment strategies. In addition, we reviewed the literature reporting TMZ efficacy in these tumors.

■ CASE REPORTS

Case 1

The first patient was a 55-year-old man who had an invasive growth hormone (GH)-secreting pituitary macroadenoma. He presented in September 2006 with headache, visual loss, perspiration, enlarged hands and feet. Physical examination demonstrated macroglossia, enlargement of hands and feet, prognathism, frontal bossing, mandibular enlargement and teeth separation. His pulse rate was 78 beats per minute and blood pressure was 150/90 mm Hg. On laboratory examination, the serum IGF-1 level was 691 ng/ml (normal range [N]; 94-284) and GH level was 2.7 mcg/L (N, 0-6.7 mcg/L). The GH level was not suppressed (> 1.9 mcg/L) after a 75-gram oral glucose load. Pituitary magnetic resonance imaging (MRI) revealed a giant macroadenoma with suprasellar extension and invasion of the right sphenoid sinus.

He underwent transnasal/transsphenoidal (TN/TS) pituitary adenectomy. The resected tissue was a GH-secreting adenoma with 10% Ki67 proliferation index and extensive P53 staining. O-6-methylguanine-DNA methyltransferase (MGMT) immunostaining was not available.

In October 2008, laboratory examination showed an elevated insulin-like growth factor-1 (IGF-1) level (352 ng/ml). Pituitary MRI demonstrated a 20 mm recurrent adenoma. Octreotide LAR treatment at a dose of 20 mg per month was initiated. He underwent right pterional craniotomy in April 2009 and stereotactic radiosurgery in July 2009 (14 Gy)(Gamma Knife, Elekta Instruments, and Stockholm, Sweden). Although octreotide LAR was continued at a dose of 30 mg/month, neither hormonal nor tumoral response was achieved. Temozolomide treatment was started at a dose of 200 mg/m²/day, for 5 days every 28 days. During the first six cycles, tumor growth was stabilized but progression occurred despite the continuation of treatment at the 12th month of treatment (Figure 1A, B). He died because of local tumor effects.

Case 2

A 29-year-old man presented with loss of libido and malaise. On physical examination, his blood pressure was 130/90 mm Hg and pulse rate was 84 beats per minute. He had abdominal purple blue wide striae, proximal muscle weakness and facial plethora. Laboratory investigations showed elevated urinary free cortisol level of 138 mcg/24 hrs (normal range [N]; 10-80 mcg/24 hrs). Cortisol suppression was not obtained after overnight 1 mg and subsequent 2 mg (classical two days) dexamethasone suppression tests (30.2 mcg/dl and 26.6 mcg/dl respectively). Plasma adrenocorticotrophic hormone (ACTH) level was normal (32 pg/ml, N;7.2-63.3 pg/ml). Pituitary MRI revealed a macroadenoma 24 mm in diameter, invading the left cavernous sinus and internal carotid artery (ICA) (Figure 2A-C). The visual field was normal. Adrenal computed tomography (CT) showed normal adrenal glands. These findings indicated ACTH-dependent Cushing's disease. The patient underwent TN/TS pituitary adenectomy. Histopathological examination showed a 99% ACTH-positive adenoma with 10% Ki67 proliferation index and extensive P53 staining.

Postsurgical pituitary MRI revealed a residual mass adjacent to the left ICA. Stereotactic radiosurgery (25Gy) (CyberKnife, Accuray, Sunnyvale, California, USA) was used for the patient due to the presence of a residual tumor on pituitary MRI and left eyelid ptosis. After this treatment, the ptosis regressed dramatically. Four months later, Pasireotide (600 µg, subcutaneously, twice daily) treatment was started. The only side effect of pasireotide was mild hyperglycemia that responded to oral antidiabetic treatment. At the second month of pasireotide therapy, right eyelid ptosis occurred. Pituitary MRI showed that the residual mass on the left side had totally disappeared but there was a new macroadenoma located on the right side of the adenohypophysis (Figure 2A-C). Radiotherapy was not planned again because of the short time period after the first session of Cyber Knife and possible side effects on the optic chiasm. The patient underwent a second TN/TS adenectomy. Immunohistochemistry revealed extensive




Figure 1: A) Pretreatment T1 coronal-weighted magnetic resonance images showing a sellar mass 37 mm in its maximum diameter, expanding the sella with a suprasellar component which elevated the right side of optic chiasm, invading the right cavernous sinus and right internal carotid artery. **B)** 12th month of Temozolomide treatment; T1 coronal MRI demonstrating progression in suprasellar component of tumor.




Figure 2: A) At the time of diagnosis; T1-weighted MRI revealed a macroadenoma 24 mm in diameter, invading the left cavernous sinus and internal carotid artery (ICA). **B)** Six months after the first session of Cyber Knife; T1-weighted MRI revealed a new adenoma located at the right side of the pituitary invading the right cavernous sinus **C)** After second TN/TS adenomectomy; T1-weighted MRI revealed a large cavitation area after total resection of adenoma, showing no residual tumor.

P53 staining (>50%) and 15% Ki67 proliferation index. MGMT staining was not available.

Although no mass was observed on pituitary MRI (Figure 2A-C), the postoperative clinical picture of patient were consistent with residual disease and the level of urinary free cortisol was 968 nmol/day (N; 38-208). Temozolomide treatment was started at a dose of 200 mg/m²/day, for 5 days every 28 days. After three cycles of TMZ, response evaluation showed progressive disease. Urinary free cortisol level was 8658 nmol/day (N; 38-208) and ACTH level was elevated to 197 pg/ml (N; 7.2-63.3). Pituitary MRI revealed a recurrent mass at the left side of the pituitary. TMZ was no longer continued because of unresponsiveness. The only side effect of TMZ was mild nausea. Left eyelid ptosis relapsed and CyberKnife treatment was applied again. The ptosis regressed after radiosurgery, but hormonal and radiological evidence of disease persisted. The patient was lost due to massive pulmonary thromboembolism.

Case 3

A 65-year-old woman presented with headache and a previous history of macroprolactinoma in November 2011. On physical examination, her blood pressure was 120/75 mm Hg and the pulse rate was 70 beats per minute. She had right eyelid ptosis and visual disturbances. Computerized visual field test revealed bitemporal superior quadranopia.

In her medical history; she had been treated with TN/TS pituitary adenomectomy in 1982. Because of tumor progression under bromocriptine treatment, she underwent right frontotemporal/orbitozygomatic craniotomy in 2005. Histology demonstrated a 90% prolactin (PRL)-positive tumor with 10% Ki67 proliferation index. One year later, pituitary MRI revealed a 38 mm adenoma invading the right cavernous sinus and compressing the optic chiasm. Right frontotemporal craniotomy and subtotal tumor excision was performed. In 2010, she was treated with stereotactic radiosurgery (14 Gy, Gamma Knife, Elekta Instruments, Stockholm, Sweden) because of tumor recurrence under bromocriptine treatment.

Radiological and biochemical progression was demonstrated under high dose (7 mg/week) cabergoline therapy in February 2012. Pituitary MRI revealed a 16 mm adenoma adjacent to right cavernous sinus (Figure 3A-C). Her prolactin level was 1012 ng/ml (N;2.7-19.6). TMZ treatment was started at 200 mg/m²/day for 5 days every 28 days. After six cycles of TMZ, PRL level decreased to 60 ng/ml and continued to fall after the cessation of therapy. Pituitary MRI revealed significant cystic degeneration of tumor with no decrease in tumor size (Figure 3A-C). Cabergoline was restarted at 1 mg/week dose. PRL level decreased to normal range two months after discontinuation of TMZ. Thirty-six months after cessation of TMZ, rapid elevation in PRL level (2877 ng/ml) and progression of tumor with increased solid component on




Figure 3: **A)** Pre-treatment MRI; T1-weighted MRI of the sellar and parasellar regions revealed a 17 mm macroadenoma invading the right cavernous sinus and compressing the optic chiasm. **B)** After three cycles of TMZ; T1-weighted MRI revealed cystic and hemorrhagic changes in adenoma and reduction of solid component of tumor. **C-**After TMZ retreatment MRI; T1-weighted MRI revealed a 32 mm tumor at the right temporal lobe extending from the sella.

MRI were observed. The cabergoline dose was increased to 7 mg/week but no response was seen. TMZ was restarted at 200 mg/m²/day, for 5 days every 28 days. After three cycles of TMZ, response evaluation revealed tumor progression on pituitary MRI and increased PRL level (3700 ng/ml) (Figure 3A-C). Surgery was recommended but the patient did not accept any medical or surgical treatment.

DISCUSSION

Several cases with aggressive pituitary adenoma or carcinoma treated with TMZ have been published during the last decade with an estimated 60-70% response rate (13,60). Favorable results were usually reported in macroprolactinomas and adrenocorticotropinomas (12,13,30,60,73). Low expression of MGMT, which is a DNA repair protein and reverses methylation caused by TMZ, was suggested as a predictor of good response to TMZ (35).

Management of macrosomatotropinoma may be more challenging, because 40-60% of them cannot be controlled with surgery, and recurrence of tumor initially thought to be cured by surgery was reported in approximately 10% of cases (8,44). However, tumor growth after radiotherapy is seen in less than 1% of patients (8). Experience with TMZ in somatotroph adenomas is limited due to low frequency of resistance to standard treatments or reporting bias. We found fourteen somatotroph tumors treated with TMZ in the literature (Table I) (6,7,12,27,43,50,72). Bengtsson et al. reported two complete and two partial responses to TMZ among six somatotroph tumors (outcome data was available for five patients) including three aggressive adenomas and three PCs (7). Partial response was seen in two aggressive tumors (one had a shift from PRL to GH secretion) and complete response with normal IGF-1 levels in two carcinomas (one had a shift from PRL to GH secretion). Efficacy of TMZ was also reported in PCs with no relapse at 48 and 91 months of therapy. One of those aggressive adenomas and both of PCs had low (9%) MGMT immunoexpression. The remaining adenoma with partial response had heterogeneous MGMT immunoexpression (9-100%) and tumor recurrence

occurred at 15th month of TMZ treatment. A somatotroph PC with high MGMT expression (90%) was reported to progress under TMZ treatment. These data may reflect the impact of lower MGMT expression as a good prognostic marker for TMZ response in aggressive macrosomatostatinomas. All other reports of somatotroph adenomas revealed unresponsiveness to TMZ therapy (6,12,27,40,43,50,72). Previously, low MGMT immunoexpression was demonstrated in a majority of somatotroph tumors (83.3%), including tumors with high Ki-67 labeling index (80). However, two of the reported MGMT negative somatotroph adenomas were non-responders, raising the concerns about significance of MGMT status (7,12,27).

In our case with aggressive somatotroph adenoma, tumor size and IGF-1 level were stable until the sixth cycle of TMZ therapy, but rapid progression occurred thereafter. Consequently, according to the current review of the literature including the present case, the response rate to TMZ among aggressive somatotroph adenomas was 26.7% (4/15).

Corticotroph adenomas are more aggressive tumors compared to other pituitary neoplasms (23,26). The five-year mortality rate has been reported as high as 50% for untreated patients (59). Remission after surgical therapy is achieved in 65-90% of ACTH-secreting pituitary microadenomas and as low as 25-30% of macroadenomas in some series (9,10,19). Relapse rate in ten years is also higher for macroadenomas (%12-36 vs. %10-20) (9). When residual or recurrent disease is observed; radiotherapy/radiosurgery, medical treatment (somatostatin receptor analogues) and bilateral adrenalectomy are the treatment options. A subgroup of corticotroph tumors is resistant to all conventional therapies. Approximately 50% of patients cannot be cured with repeated surgery (64). When the MGMT status of invasive and recurrent corticotroph adenomas was investigated, low immunoexpression was demonstrated in 60% and 86% of these tumors, respectively (66). Nelson syndrome and Crouse cell macroadenomas were also reported to have low MGMT expression in most cases (66,71). According to these limited data, TMZ has been

suggested as a salvage therapy for recurrent or incurable Cushing disease. Approximately 70% of Cushing's disease patients have been reported to be responsive to TMZ (29). Depending on the previous case reports, the sensitivity and specificity of the MGMT status in predicting TMZ responsiveness of corticotroph tumors was reported to be 80% and 70% respectively (2).

Forty-nine cases of corticotroph tumors treated with TMZ have been reported in the literature so far (Table II). Among them, 25 PR and 5 CR were noted (Table II). Consequently, according to the current review of the literature, including the present case, the frequency of complete and partial response to TMZ among aggressive corticotroph tumors was 10% and 50%, respectively. The duration of response was unavailable or quite limited for most cases. The longest lasting effect of TMZ in a corticotroph tumor was 30 months after stopping therapy (12). Five patients had complete response under TMZ treatment (16,29,41,71). One of them had an MGMT positive tumor and others had negative or low MGMT immunoreexpression. Eight partial responders were reported to have low or negative MGMT immunoreexpression (Table II). Three patients were reported to be non-responders despite negative to low MGMT staining. Unfortunately, MGMT status was not available in the remaining twelve patients, including the present case (Table II).

Approximately 90% of prolactinomas are responsive to dopamine agonists (48). Aggressive macroprolactinomas are

described as dopamine agonist resistant tumors. In most cases, resistance to dopamine agonists develop due to patient in compliance or estrogen replacement (49). Moreover, malignant transformation of the tumor is also reported (31). In cabergoline resistant tumors, surgery generally fails to normalize PRL. TMZ was shown to have efficacy on aggressive macroprolactinomas and is recommended for the treatment of malignant prolactinoma in the recent clinical practice guideline of the Endocrine Society (45). In the literature, according to our best knowledge, 45 aggressive macroprolactinomas treated with TMZ have been reported (Table III). Only three patients (6.5%) achieved complete response and all of them had negative/low MGMT immunoreexpression (7,22,24,29). Excitingly, one patient was reported to be in remission at 91 months follow-up (7). Twenty-eight patients (60.8%) were partial responders. Four patients with negative MGMT immunoreexpression were resistant to TMZ (16,29,40,61). The MGMT status was unknown in 15 tumors. Even though a partial response under TMZ treatment was achieved initially in the present case with prolactinoma, recurrence was seen after cessation of treatment and tumor progression was detected with re-treatment. Campderá et al. also reported unresponsiveness to second course of TMZ treatment in two previously responsive patients (15). Recently, Strowd et al. reported a case of recurrent macroprolactinoma re-treated with TMZ (69). They observed rapid PRL reduction and partial response on MRI after four cycles. Long term follow-up after re-treatment was not available.

Table I: Case Reports and Series of Temozolomide Treatment in Somatotroph Tumors

Author, year	Age (years)	Sex	Type	Other treatments	MGMT status (IHC)	TMZ Dose and cycles	Response
McCormack et al. (43); 2009	48	M	PA	PS, RT, SLA, DA	Positive	150 mg/m ² , 3 c	NR
Morin et al. (50); 2012	22	M	PA	PS, RT, Pegvisomant	NA	200 mg/m ² , 5 c	NR
Batisse et al. (6); 2013	47	M	PA	PS, RT, SLA, Cisplatin, Adriamycin	High (90%)	200 mg/m ² , 3 c	NR
	54	F	PC	PS, RT, SLA	68%	150-200 mg/m ² , 7 c	NR(SD)
Ghazi et al. (27); 2015	39	M	PA	PS	Negative	150 mg/m ² , 8 c	NR
Bengtsson et al. *(7); 2015	31**	F	PA	PS, RT, SLA, lomustine	Heterogeneous	150-200 mg/m ² , 6 c	PR
	13**	F	PA	PS, RT, DA, SLA, lomustine	High (95%)	150-200 mg/m ² , NA	NA
	46	M	PC	PS, RT, SLA, Pegvisomant	High (90%)	150-200 mg/m ²	NR
	40	F	PC	PS, RT, DA	Low (9%)	150-200 mg/m ² , 6	CR
Bruno et al. (12); 2015	34	F	PA	PS, SLA, DA	Negative	320 mg/d, 4 c	NR
Losa et al. (41), 2015	NA	NA	NA	NA	NA	150-200 mg/m ² , NA	NR (SD)
	NA	NA	NA	NA	NA	150-200 mg/m ² , NA	NR (SD)
Our patient		M	PA	PS, RT, SLA, Pegvisomant	NA	200 mg/m ² , 3 c	NR

F: Female, **M:** Male, **PC:** Pituitary carcinoma, **PA:** Pituitary adenoma, **PS:** Pituitary surgery, **RT:** Radiotherapy, **DA:** Dopamine agonist, **SLA:** Somatostatin ligand antagonist, **KNZ:** Ketoconazole; **NA:** Not available, **NR:** Non-responder, **PR:** Partial response, **CR:** Complete response, **SD:** Stable disease.

*Two patients with prolactinoma with further GH secretion from this series are given in Table III. One of the cases was also reported by Hagen et al. in 2009 (28). **These two patients were previously reported by Asimakopoulou et al. in 2014 (4).

Table II: Case Reports and Series of Temozolomide Treatment in Corticotroph Tumors

Author, year	Age	Sex	Subtype	Other treatments	MGMT status (IHC)	TMZ Dose and cycles	Response
Kovacs et al*(35), 2008	38	M	PC, Silent	PS, RT	High	150-200 mg/d, 8	NR
Moyes et al. (52), 2009	64	F	PA (Nelson's)	PS, RT, DA, BA	Negative	200 mg/m ² , 6	PR
Mohammed et al.(47), 2009	43	F	PA (Crooke cell)	Surgery, RT	Negative	150-200 mg/m ² , 12 c	PR
	60	M	PA (Crooke cell)		Positive	150-200 mg/m ² , 12 c	PR
Takeshita et al.(71), 2009	46	F	PA→PC (Crooke cell)	PS, RT, DA,SRL, glitazone, mitotane	Low	150 mg/m ² , 18 +****	CR
Bush et al.(13), 2010	NA	NA	PA	PS, RT	Low	150-200 mg/m ² ,11	PR
Raverot et al. (61), 2010	37	M	PC	PS, RT, BA	Intermediate	150-200 mg/m ² , 14	NR
	52	M	PC	PS, RT, Mitotane	Intermediate	150-200 mg/m ² , 6	PR
	50	F	PA	PS, RT, Mitotane	Negative	150-200 mg/m ² , 4	PR
	54	M	PA	PS, RT	Low	150-200 mg/m ² , 7	NR
Curto et al.(21), 2010	42	M	PC	PS, RT	Low	150 mg/m ² , 6	PR
Bode et al.(11)**2010	45	F	PC	PS, RT, BA, SRL, Glitazone	NA	150 mg/m ² , 12	PR
Losa et al.(41), 2010	52	M	PC	PS, RT	Negative	150-200 mg/m ² , 12	CR
	53	F	PA	PS, RT	Positive	150-200 mg/m ² , 6	NR
	55	F	PA	RT, SRL	Positive	150-200 mg/m ² , 12	NR (SD)
	64	M	PA	PS, RT, SRL, DA	NA	150-200 mg/m ² , 3	NR
Dillard et al. (23), 2011	56	M	PA	PS, RT	NA	200 mg/m ² , 6	PR
Jouanneau et al.(32), 2012	45	M	PC, Silent	PS, RT, BA	NA	200 mg/m ² , NA	NR
Scheithauer et al. (67), 2012	1	F	Pituitary blastoma,	PS	Intermediate (40-60%)	100 mg/d, 12 c	PR
Rotondo et al.(62), 2012	49	F	PA (Crooke cell)	PS,RT	Negative	85 mg/d, NA	NA
Arnold et al.(3), 2012	61	F	PC	PS,RT	NA	NA, 12 mo.	NR (P)
Annamalai et al.(2), 2012	65	M	PC	PS, RT, KNZ, metyrapone,	Low	200 mg/m ² , 15	PR
Hirohata et al.(29), 2013	42	F	PC (Crooke cell)	NA	Negative	150-200 mg/m ² , 8	PR
	53	F	PC(Crooke cell)	NA	Positive	150-200 mg/m ² , 20	CR
	57	M	PC	NA	Positive	150-200 mg/m ² , 8	NR (SD)
	45	F	PA (Crooke cell)	NA	Positive	150-200 mg/m ² , 11	PR
Cornell et al.(20), 2013	40	M	PA (Silent→CS)	PS, RT, Mifepristone	NA	200 mg/m ² , 6	NR (P)
Asimakopoulou et al.(4), 2014	55	F	PA (Crooke Cell)	PS, RT, KNZ, Metyrapone	NA	150-200 mg/m ² , 11	PR
Mendolia et al.(46), 2014	58	M	PC	PS, RT, KNZ, DA, BA	NA	160 mg/m ² , 1	NA

Table II: Cont.

Author, year	Age	Sex	Subtype	Other treatments	MGMT status (IHC)	TMZ Dose and cycles	Response
Bengtsson et al.(7), 2015	51	M	PC	PS, RT, BA	Heterogeneous	150-200 mg/m ² , 8 c	PR
	62	M	PC (Nelson's)	PS, RT, BA, DA	High (95%)	150-200 mg/m ² , 12c	NR
	70	M	PC	PS, RT, DA, Pasireotide, KNZ	Low (9%)	150-200 mg/m ² , 6 c	NR
	71	F	PA	PS, RT	High (90%)	150-200 mg/m ² , 1 c	NA
Ceccato et al.(16),2015	32	M	PA	PS, RT	NA	150-200 mg/m ² , 24 c	PR
	47	M	PA (Silent→CS)	PS, RT	NA	150-200 mg/m ² , 24 c	NR (SD)
Bruno et al.(12), 2015	39	F	PA (Nelson's)	PS, RT,	Negative	240 mg/d, 6	NR
	42	F	PA	PS	Negative	250 mg/d, 13	CR
	52	F	PA	PS, KNZ	Negative	180 mg/d, 29	CR
Kurowska et al.(36), 2015	56	F	ACTH (Nelson's)	PS, RT, Mitotane, KNZ, BA	Very Low	150 mg/m ² , 9	PR
Campdera et al.(15), 2015	50	M	PA	PS, RT, KNZ	Negative	200 mg/m ² , 7	PR
	30	M	PA	PS, RT	Positive (>50%)	200 mg/m ² , 12	PR
	42	M	PA	PS, RT, BA	NA	150-200 mg/m ² , 6	PR
Losa et al.(40), 2015*****	NA	NANA	NA	NA	NA	150-200 mg/m ²	PR
	NA	NA	NA	NA	NA	150-200 mg/m ²	PR
	NA	NA	NA	NA	NA	150-200 mg/m ²	PR
	NA	NA	NA	NA	NA	150-200 mg/m ²	PR
	NA	NA	NA	NA	NA	150-200 mg/m ²	NR
	NA	NA	NA	NA	NA	150-200 mg/m ²	NR
Our Patient	M	PA	PS, RT, Pasireotide	NA	NA	200 mg/m ² , 3	NR

F: Female, **M:** Male, **PC:** Pituitary carcinoma, **PA:** Pituitary adenoma, **PS:** Pituitary surgery, **RT:** Radiotherapy, **DA:** Dopamine agonist, **SLA:** Somatostatin ligand antagonist, **KNZ:** Ketoconazole, **NA:** Not available, **NR:** Non-responder, **PR:** Partial response, **CR:** Complete response, **PD:** Progression, **SD:** Stable disease.

*Same patient was reported by Moshkin et al. and Ortiz et al. as progression to carcinoma occurred after TMZ administration and long term stabilization of tumor was achieved with Bevacizumab therapy (51,56).

PR was achieved with TMZ and SOM230 combination therapy.* PR was achieved with TMZ and Capecitabine combination therapy. Re-growth was detected at the fifth month of the regimen.

****TMZ was given monthly in the first and bimonthly in the second year of treatment.

***** This cohort included 7 corticotroph tumors previously reported by Ceccato et al, Curto et al. and Losa et al. (16,21,41)

Table III: Case Reports and Series of Temozolomide Treatment in Mammotroph Tumors

Author, year	Age Years	Gender	Subtype	Other treatments	MGMT status (IHC)	TMZ Dose and cycles	Response
Zhu et al.(79), 2004	61	M	PC	NA	NA	NA	PR
Syro et al.(70), 2006	46	M	PA	PS, RT, DA	NA	200 mg/m ² /d, 7	PR
Fadul et al.(24), 2006	36	M	PC	PS, RT, DA, SLA, Carboplatin, Paclitaxel, Etoposide	NA	200 mg/m ² /d, 10	PR
Lim et al.(38), 2006	77	M	PC	PS, RT, DA,	NA	200 mg/m ² /d, 18	PR
Neff et al.(54), 2007	52	F	PA	PS, RT, DA, SLA	NA	150 mg/m ² /d, 26	PR
Kovacs et al.(34), 2007	46	M	PC	PS, RT, DA	NA	200 mg/m ² , 7	PR
Debono et al.(22), 2008	47	M	PA (MEN1)	PS, RT, DA	Low	150-200 mg/m ² , 11	PR
Hagen et al.(28), 2009	60	M	PA	PS, DA, SLA	Low (9%)	150-200 mg, 12	PR
Bengtsson et al.(7), 2015	49	F	PC (+GH)	PS, RT, DA, SLA	Low (9%)	150-200 mg, 23	CR
McCormack et al.(43), 2009	65	F	PC	PS, RT, DA, SLA	Negative	200 mg/m ² , 4	PR
Byrne et al.(14), 2009	64	M	PC	PS, DA	NA	200 mg/m ² , 12	PR
Losa et al.(41), 2010	62	M	PA	PS, RT, DA	Negative	200 mg/m ² , 12	NR (SD) PR
	57	F	PA	PS, RT, DA	NA***	200 mg/m ² , 12	
Raverot et al.(61), 2010	43	M	PC	PS,RT, DA	NA	150-200 mg/m ² , 24	PR
	71	M	PA	PS,RT, DA	30%	150-200 mg/m ² , 8	NR
	69	M	PC	PS,RT, DA	Negative	150-200 mg/m ² , 5	NR
	47	F	PC	PS,RT, DA	100%	150-200 mg/m ² , 3	NR
Bush et al.(13), 2010	NA	NA	PA	NA	Low (<10%)	75 mg (21/7), 11	PR
Murakami et al.(53), 2011	60	F	PA	PS, RT, DA	Negative	200 mg/m ² , 10	PR
Phillips et al.(58), 2012	28	M	PC (MEN1)	PS, RT, DA	NA	350 mg, 1	NR
Phillipon et al.(57), 2012	41	M	PA (MEN1)	PS, RT, DA	NA	200 mg/m ² , 24	PR
Whitelaw et al.(73), 2012	39	M	PA	PS, RT, DA	Negative	200 mg/m ² , 6	PR
	32	M	PA	PS, DA	Negative	200 mg /m ² , 6	PR
	15	M	PA	PS, DA	Negative	200 mg/m ² , 12	PR
Chentli et al.(18), 2013	27	F	PA	PS, DA, SLA	NA	5 mg/d	PR
Hirohata et al.(29), 2013	66	F	PA	NA	Negative	150-200 mg/m ² , 20	CR
	49	F	PA	NA	Negative	150-200 mg/m ² , 3	NR(P)
	60	M	PC	NA	Negative	150-200 mg/m ² , 24	PR
	60	F	PC	NA	Positive	150-200 mg/m ² , 12	PR
	60	F	PC	NA	Negative	150-200 mg/m ² , 10	CR
Zemmoura et al.(77), 2013	54	M	PC	PS, RT,DA	NA	200 mg/m ² , 5	NR

Table III: Cont.

Author,year	Age Years	Gender	Subtype	Other treatments	MGMT status (IHC)	TMZ Dose and cycles	Response	
Bengtsson et al.(7), 2015	33	M**	PA (+GH)	PS, DA, SLA	Low (10%)	150-200 mg/m ² , 3	PR	
	22	M	PA	PS, RT, DA, SLA	High (90%)	150-200 mg/m ² , 15	NR	
	34	M	PA	PS, RT, DA	Intermediate (9-100)	150-200 mg/m ² , 3	PR *	
	45	M	PA	PS, RT, DA, Lomustine	High (100%)	150-200 mg/m ² , 18	NR	
	55	M	PA	PS, RT, SA, SLA	Intermediate (50%)	150-200 mg/m ² , 11	PR	
	68	M	PA	PS, DA	Low (9%)	150-200 mg/m ² , 1	NA	
	23	M	PA	PS, RT, DA, SLA, Pasireotide	High (100%)	150-200 mg/m ² , 4	NR	
				PC	PS, RT, DA, SLA	Intermediate (50%)	150-200 mg/m ² , 14	
	32	F	PC	PS, DA	NA	150-200 mg/m ² , 19	NR	
	59	F					PR	
Bruno et al.(12), 2015	78	M	PC	PS, RT, DA	Negative	140 mg/d, 1c	NA	
Strowd et al.(69), 2015	44	F	PA	PS, RT, DA	NA	150-200 mg/m ² , 3	PR	
Losa et al.(40),**** 2015	NA	NA	NA	NA	NA	150-200 mg/m ²	PR	
	NA	NA	NA	NA	NA	150-200 mg/m ²	NR(SD)	
	NA	NA	NA	NA	NA	150-200 mg/m ²	NR	
Our patient	65	F	PA	PS, RT, DA	NA	200 mg/m ² , 6	PR	

F: Female, **M:** Male, **PC:** Pituitary carcinoma, **PA:** Pituitary adenoma, **PS:** Pituitary surgery, **RT:** Radiotherapy, **DA:** Dopamine agonist, **SLA:** Somatostatin ligand antagonist, **NA:** Not available, **NR:** Non-responder, **PR:** Partial response, **CR:** Complete response, **PD:** Progression, **SD:** Stable disease, **MEN1:** Multiple Endocrine Neoplasia Type 1.

*Stable tumor, PRL normalized at follow-up.

**This patient was previously reported by Asimakopoulou et al. in 2014 (4).

***Completely negative staining of tumor but also negative control.

****This cohort included 2 mammothroph tumors previously reported by Losa et al.(40).

According to all reported cases, the overall response rates to TMZ in prolactinoma, corticotropinoma and somatostatinoma are 67.3%, 60% and 26.7% respectively. Previously, TMZ responsiveness was reported in 60% of aggressive adenomas and 69% of PCs (60). A subsequent review of the four cohorts revealed 55.5% and 41% partial response in aggressive adenomas and PCs (65). Even with such analyses indicating a TMZ response rate, the efficacy of TMZ in pituitary tumors is not easy to establish because of distinct response criteria and limited clinical trials. A recent case series defined complete response as complete regression of tumor mass and normalization of hormone levels. Decrease in tumor volume $\geq 30\%$ and/or hormone concentrations $\geq 50\%$ were accepted as partial response (7). They reported partial response in 6 of 13 evaluable patients with locally aggressive adenomas treated with TMZ. Another study from Japan classified effectiveness of TMZ according to Response Evaluation Criteria in Solid Tumors (RECIST) version 2.0. Complete response was defined as disappearance of target lesion and partial response was defined as $\geq 30\%$ decrease in the sum of diameters of the target lesion (29). Decrease in hormone concentrations was not included in these response criteria. They achieved complete or partial response in 10

out of 13 subjects but noted that recurrence occurred in 6 (46%) patients after an effective response. As mentioned above, a patient who was accepted as a responder may be a non-responder according to different criteria or vice versa. Also, it is not clear whether or not patients with stable tumors should be accepted as responders. A recent analysis of Italian patients who were treated with TMZ revealed disease control in 25/31 (80.6 %) of cases when stable tumors were included. However, reduction of tumor size or hormonal normalization was achieved only in 35.5% and 28.6% of the patients, respectively (40). Moreover, the reported response rates might have been overestimated due to more frequent reporting of responders than non-responders as well. Therefore, a uniform description of response criteria is needed for reliable evaluation of TMZ responsiveness.

MGMT immunoreexpression status is the most commonly studied factor affecting TMZ responsiveness. Immunohistochemistry is the preferred method for detection of MGMT status in pituitary tumors (43). In 2008, Kovasc et al. suggested a relationship between TMZ responsiveness and MGMT status (35). McCormack et al. and Whitelaw et al. observed a significant association between MGMT negative tumor staining

and favorable response to TMZ (43,73). Recently, Bengtsson et al. demonstrated lower MGMT immunoreexpression in TMZ responders compared to non-responders (median 9% vs. 93%, $p < 0.01$) and concluded that a MGMT level below 50% was a predictor of response to TMZ (7). Conversely, two studies reported resistance to TMZ in MGMT negative PCs although they achieved response in tumors with only low to moderate MGMT expression (13,61). These results indicate that additional factors are related with the efficacy of TMZ treatment. Resistance to TMZ due to DNA mismatch repair protein (MSH6) mutation was also reported in APAs and PCs (29). However, the impact of these mutations as predictors of the response to TMZ is not well-established and routine immunohistochemical assessment of MGMT or MSH is not recommended.

Biochemical and radiological assessment is recommended after three cycles of temozolomide treatment (61). If there is no response, resistance to drug is indicated. Further progression or unresponsiveness was also reported in initial TMZ responders. Intensified TMZ regimens were proposed to lower MGMT expression but this finding was not confirmed in pituitary adenomas (74). Sensitization of glioblastoma cells to TMZ effect by Disulfiram was demonstrated (78). Zhao et al. observed that Disulfiram sensitized pituitary adenoma cells to TMZ in vitro by reducing MGMT protein expression. Down-regulation of MGMT expression with HIF-1 α (Hypoxia-inducible factor 1 α) was suggested as a potential method to improve TMZ sensitization (17). Unfortunately clinical data about these potential methods is not available yet. Alternative treatment options for TMZ resistant tumors include TMZ-pasireotide and TMZ-capecitabine combinations (16). Successful treatment of aggressive Cushing Disease with the CAPTEM protocol (Capecitabine and TMZ combination) was reported in case reports and a recent small case series (61,75). Target of rapamycin inhibitor (everolimus), and targeted therapies (anti-vascular endothelial growth factor, epidermal growth factor receptor), were also reported on a case report basis (37,41,56).

■ CONCLUSION

Approximately 50% of aggressive pituitary adenomas and carcinomas are responsive to TMZ. However, uniformly defined response criteria and relevant durations of response are still lacking. Clinical trials are also needed to identify treatment regimens for TMZ resistant pituitary tumors.

■ REFERENCES

- Al-Shraim M, Asa SL: The 2004 World Health Organization classification of pituitary tumors: What is new? *Acta Neuropathol* 111:1-7, 2006
- Annamalai AK, Dean AF, Kandasamy N, Kovacs K, Burton H, Halsall DJ, Shaw AS, Antoun NM, Cheow HK, Kirolos RW, Pickard JD, Simpson HL, Jefferies SJ, Burnet NG, Gurnell M: Temozolomide responsiveness in aggressive corticotroph tumours: A case report and review of the literature. *Pituitary* 15:276-287, 2012
- Arnold PM, Ratnasingam D, O'Neil MF, Johnson PL: Pituitary carcinoma recurrent to the lumbar intradural extramedullary space: Case report. *J Spinal Cord Med* 35:118-121, 2012
- Asimakopoulou A, Tzanela M, Koletti A, Kontogeorgos G, Tsagarakis S: Long-term remission in an aggressive Crouke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide. *Clin Case Rep* 2:1-3, 2014
- Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K, Sartorius SE, Dugan M, Cutler D, Batra V, Grochow LB, Donehower RC, Rowinsky EK: Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. *Clin Cancer Res* 5:309-317, 1999
- Batisse M, Raverot G, Maqdasy S, Durando X, Sturm N, Montoriol PF, Kemeny JL, Chazal J, Trouillas J, Tauveron I: Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. *Cancer Invest* 31:190-196, 2013
- Bengtsson D, Schroder HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, Rasmussen AK, Johannsson G, Hoybye C, van der Lely AJ, Petersson M, Ragnarsson O, Burman P: Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. *J Clin Endocrinol Metab* 100:1689-1698, 2015
- Besser GM, Burman P, Daly AF: Predictors and rates of treatment-resistant tumor growth in acromegaly. *Eur J Endocrinol* 153:187-193, 2005
- Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M: Treatment of adrenocorticotropin-dependent Cushing's syndrome: A consensus statement. *J Clin Endocrinol Metab* 93:2454-2462, 2008
- Blevins LS Jr, Christy JH, Khajavi M, Tindall GT: Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas. *J Clin Endocrinol Metab* 83:63-67, 1998
- Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP, Thome C: SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. *Exp Clin Endocrinol Diabetes* 118:760-763, 2010
- Bruno OD, Juarez-Allen L, Christiansen SB, Manavela M, Danilowicz K, Vigovich C, Gomez RM: Temozolomide therapy for aggressive pituitary tumors: Results in a small series of patients from Argentina. *Int J Endocrinol* 2015:587893, 2015
- Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML, Thorner MO, Laws ER Jr, Lopes MB: Temozolomide treatment for aggressive pituitary tumors: Correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. *J Clin Endocrinol Metab* 95:E280-290, 2010
- Byrne S, Karapetis C, Vrodos N: A novel use of temozolomide in a patient with malignant prolactinoma. *J Clin Neurosci* 16:1694-1696, 2009

15. Campdera M, Palacios N, Aller J, Magallon R, Martin P, Saucedo G, Lilienfeld H, Estrada J: Temozolomide for aggressive ACTH pituitary tumors: Failure of a second course of treatment. *Pituitary* 19(2):158-166, 2016
16. Ceccato F, Lombardi G, Manara R, Emanuelli E, Denaro L, Milanese L, Gardiman MP, Bertorelle R, Scanarini M, D'Avella D, Occhi G, Boscaro M, Zagonel V, Scaroni C: Temozolomide and pasireotide treatment for aggressive pituitary adenoma: Expertise at a tertiary care center. *J Neurooncol* 122:189-196, 2015
17. Chen W, Xiao Z, Zhao Y, Huang L, Du G: HIF-1 α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression. *Oncol Rep* 30:2495-2501, 2013
18. Chentli F, Yaker FA, Azzoug S, Belhimer F: Temozolomide: Anti-tumor effect on giant, invasive and resistant pediatric prolactinoma. *Indian J Endocrinol Metab* 17:1136-1138, 2013
19. Ciric I, Zhao JC, Du H, Findling JW, Molitch ME, Weiss RE, Refetoff S, Kerr WD, Meyer J: Transsphenoidal surgery for Cushing disease: Experience with 136 patients. *Neurosurgery* 70:70-80; discussion 80-71, 2012
20. Cornell RF, Kelly DF, Bordo G, Carroll TB, Duong HT, Kim J, Takasumi Y, Thomas JP, Wong YL, Findling JW: Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiency. *Case Rep Endocrinol* 2013:675298, 2013
21. Curto L, Torre ML, Ferrau F, Pitini V, Altavilla G, Granata F, Longo M, Hofland LJ, Trimarchi F, Cannavo S: Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease-Report of a case and literature review. *Scientific World Journal* 10:2132-2138, 2010
22. Debono M, Bridgewater C, Ross R, Newell-Price J: Treating an aggressive prolactinoma in a patient with MEN 1: Beneficial response to temozolomide. *Society for Endocrinology BES; Endocrine Abstracts*, 15:188, 2008
23. Dillard TH, Gultekin SH, Delashaw JB Jr, Yedinak CG, Neuwelt EA, Fleseriu M: Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. *Pituitary* 14:80-91, 2011
24. Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE: Long-term response of pituitary carcinoma to temozolomide. Report of two cases. *J Neurosurg* 105:621-626, 2006
25. Fernandez A, Karavitaki N, Wass JA: Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK). *Clin Endocrinol* 72:377-382, 2010
26. George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr, Lloyd RV, Meyer FB: Crooke's cell adenoma of the pituitary: An aggressive variant of corticotroph adenoma. *Am J Surg Pathol* 27:1330-1336, 2003
27. Ghazi AA, Rotondo F, Kovacs K, Amirbaigloo A, Syro LV, Fathalla H, Di Ieva A, Cusimano MD: Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature. *Endocr Pathol* 26:135-139, 2015
28. Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M: Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. *Eur J Endocrinol* 161:631-637, 2009
29. Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A: DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: The national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. *J Clin Endocrinol Metab* 98:1130-1136, 2013
30. Hirohata T, Ishii Y, Matsuno A: Treatment of pituitary carcinomas and atypical pituitary adenomas: A review. *Neurol Med Chir* 54:966-973, 2014
31. Hurel SJ, Harris PE, McNicol AM, Foster S, Kelly WF, Baylis PH: Metastatic prolactinoma: Effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression. *J Clin Endocrinol Metab* 82:2962-2965, 1997
32. Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J, Trouillas J, Raverot G: New targeted therapies in pituitary carcinoma resistant to temozolomide. *Pituitary* 15:37-43, 2012
33. Kaltsas GA, Evanson J, Chrisoulidou A, Grossman AB: The diagnosis and management of parasellar tumours of the pituitary. *Endocr Relat Cancer* 15:885-903, 2008
34. Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE: Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. *Human Pathol* 38:185-189, 2007
35. Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC: MGMT immunoreexpression predicts responsiveness of pituitary tumors to temozolomide therapy. *Acta Neuropathol* 115:261-262, 2008
36. Kurowska M, Nowakowski A, Zielinski G, Malicka J, Tarach JS, Maksymowicz M, Denew P: Temozolomide-induced shrinkage of invasive pituitary adenoma in patient with Nelson's Syndrome: A case report and review of the literature. *Case Rep Endocrinol* 2015:623092, 2015
37. Laws ER Jr, Morris AM, Maartens N: Gliadel for pituitary adenomas and craniopharyngiomas. *Neurosurgery* 53:255-269; discussion 259-260, 2003
38. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP: Temozolomide: A novel treatment for pituitary carcinoma. *Lancet Oncol* 7:518-520, 2006
39. Lloyd RV, KK YWJ, Farrel WE, Asa SL, Truillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E, DeLellis RA, Heitz PU: Pituitary tumors. In: DeLellis R, Lloyd R, Heitz P, Eng C (eds). *WHO Classification of Tumors of the Endocrine Organs: Pathology and Genetics of Endocrine Organs*. 2004
40. Losa M, Bogazzi F, Cannavo S, Ceccato F, Curto L, De Marinis L, Iacovazzo D, Lombardi G, Mantovani G, Mazza E, Minniti G, Nizzoli M, Reni M, Scaroni C: Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. *J Neurooncol* 126(3):519-525, 2016

41. Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangini MG, Talarico A, Mortini P, Reni M: Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: Experience in six cases. *Eur J Endocrinol* 163:843-851, 2010
42. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L: Triazene compounds: Mechanism of action and related DNA repair systems. *Pharmacol Res* 56:275-287, 2007
43. McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ: Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. *Clin Endocrinol* 71:226-233, 2009
44. Melmed S: Acromegaly pathogenesis and treatment. *J Clin Invest* 119:3189-3202, 2009
45. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA; Endocrine Society: Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 96:273-288, 2011
46. Mendola M, Passeri E, Ambrosi B, Corbetta S: Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma. *J Clin Endocrinol Metab* 99:2623-2624, 2014
47. Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD: Use of temozolomide in aggressive pituitary tumors: Case report. *Neurosurgery* 64:E773-774; discussion E774, 2009
48. Molitch ME: The cabergoline-resistant prolactinoma patient: New challenges. *J Clin Endocrinol Metab* 93:4643-4645, 2008
49. Molitch ME: Management of medically refractory prolactinoma. *J Neurooncol* 117:421-428, 2014
50. Morin E, Berthelet F, Weisnagel J, Bidlingmaier M, Serri O: Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. *Pituitary* 15:97-100, 2012
51. Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K: Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: The role of temozolomide therapy. *Hormones* 10:162-167, 2011
52. Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K, Monson JP, Plowman PN, Drake WM: Treatment of Nelson's syndrome with temozolomide. *Eur J Endocrinol* 160:115-119, 2009
53. Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, Ishida Y, Takano K, Okinaga H, Matsuno A: A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: Case report. *Neurosurgery* 68:E1761-1767; discussion E1767, 2011
54. Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS, Lechan RM: Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. *Pituitary* 10:81-86, 2007
55. Nomikos P, Buchfelder M, Fahlbusch R: The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. *Eur J Endocrinol* 152:379-387, 2005
56. Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, Rotondo F, Horvath E, Kovacs K: Anti-VEGF therapy in pituitary carcinoma. *Pituitary* 15:445-449, 2012
57. Philippon M, Morange I, Barrie M, Barlier A, Taieb D, Dufour H, Conte-Devolx B, Brue T, Castinetti F: Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. *Ann Endocrinol (Paris)* 73:225-229, 2012
58. Phillips J, East HE, French SE, Melcescu E, Hamilton RD, Nicholas WC, Fratkin JF, Parent AD, Luzardo G, Koch CA: What causes a prolactinoma to be aggressive or to become a pituitary carcinoma? *Hormones* 11:477-482, 2012
59. Plotz CM, Knowlton AI, Ragan C: The natural history of Cushing's syndrome. *Am J Med* 13:597-614, 1952
60. Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J, Brue T: Pituitary carcinomas and aggressive pituitary tumours: Merits and pitfalls of temozolomide treatment. *Clin Endocrinol* 76:769-775, 2012
61. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia JG, Bernier M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T: Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: A French multicenter experience. *J Clin Endocrinol Metab* 95:4592-4599, 2010
62. Rotondo F, Cusimano M, Scheithauer BW, Coire C, Horvath E, Kovacs K: Atypical, invasive, recurring Crouse cell adenoma of the pituitary. *Hormones* 11:94-100, 2012
63. Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S: Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. *Eur J Endocrinol* 156:203-216, 2007
64. Salehi F, Scheithauer BW, Kovacs K, Horvath E, Syro LV, Sharma S, Manoranjan B, Cusimano M: O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas. *Neurosurgery* 70:491-496; discussion 496, 2012
65. Salehi F, Scheithauer BW, Kros JM, Lau Q, Fealey M, Erickson D, Kovacs K, Horvath E, Lloyd RV: MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. *J Neurooncol* 104:647-657, 2011
66. Salehi F, Scheithauer BW, Moyes VJ, Drake WM, Syro LV, Manoranjan B, Sharma S, Horvath E, Kovacs K: Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome. *Endocr Pathol* 21:227-229, 2010
67. Scheithauer BW, Horvath E, Abel TW, Robital Y, Park SH, Osamura RY, Deal C, Lloyd RV, Kovacs K: Pituitary blastoma: A unique embryonal tumor. *Pituitary* 15:365-373, 2012
68. Scheithauer BW, Kurtkaya-Yapici O, Kovacs KT, Young WF Jr, Lloyd RV: Pituitary carcinoma: A clinicopathological review. *Neurosurgery* 56:1066-1074; discussion 1066-1074, 2005
69. Strowd R, Salvatori R, Latterra J: Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response. *J Oncol Pharm Pract* 22(3):517-522, 2016

70. Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, Kovacs K: Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. *Clin Endocrinol* 65:552-553, 2006
71. Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, Oyama K, Ohashi K, Sano T, Takeuchi Y, Yamada S: High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. *Eur J Endocrinol* 161:553-559, 2009
72. Vieira Neto L, Chimelli L, Pereira PJ, Gasparetto EL, Bines J, Wildemberg LE, Gadelha MR: The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma. *Endocr Pract* 19:e145-149, 2013
73. Whitelaw BC, Dworakowska D, Thomas NW, Barazi S, Riordan-Eva P, King AP, Hampton T, Landau DB, Lipscomb D, Buchanan CR, Gilbert JA, Aylwin SJ: Temozolomide in the management of dopamine agonist-resistant prolactinomas. *Clin Endocrinol* 76:877-886, 2012
74. Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U, Hau P: Rechallenge with temozolomide in patients with recurrent gliomas. *J Neurol* 256:734-741, 2009
75. Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M, Remotti H, Lignelli A, Fine RL: High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): A case series. *Neurosurgery* 74:E447-455; discussion E455, 2014
76. Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr: Atypical pituitary adenomas: Incidence, clinical characteristics, and implications. *J Neurosurg* 114:336-344, 2011
77. Zemmoura I, Wierinckx A, Vasiljevic A, Jan M, Trouillas J, Francois P: Aggressive and malignant prolactin pituitary tumors: Pathological diagnosis and patient management. *Pituitary* 16:515-522, 2013
78. Zhao Y, Xiao Z, Chen W, Yang J, Li T, Fan B: Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression. *Mol Med Rep* 12:2313-2322, 2015
79. Zhu Y SH, Hakimian B, Bonert V, Lim S, Heaney AP: Temodar: Novel treatment for pituitary adenoma (abstract). *US Endocr Soc* 138:43-45, 2004
80. Zuhur SS, Tanik C, Karaman O, Velet S, Cil E, Ozturk FY, Ozkayalar H, Musluman AM, Altuntas Y: MGMT immunoeexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern. *Endocrine* 40:222-227, 2011